title: Outcomes of overlapping heterogeneous drug-eluting stents versus homogeneous drug-eluting stents for diffuse lesions in small coronary arteries.
abstract: OBJECTIVE
  To investigate the outcomes of overlapping drug-eluting stenting (DES) in small and diffuse lesions.
  
  
  BACKGROUND
  Clinical outcomes of overlapping heterogeneous versus homogeneous DES of diffuse lesions (requiring ≥ 30 mm of length) in small coronary arteries (requiring ≤ 2.75 mm of diameter) are unknown.
  
  
  METHODS
  From January 2005 to December 2009, there were 99 patients with diffuse lesions in small coronary arteries receiving overlapping heterogeneous DES, and 558 patients receiving overlapping homogeneous DES at our institution. The clinical end-point of the study included in-hospital and 12-month major adverse cardiac events (death, nonfatal myocardial infarction, and target vessel revascularization (TVR).
  
  
  RESULTS
  There were no statistically significant differences between overlapping heterogeneous and homogeneous DES groups in-hospital (2.0% vs. 1.4%, respectively; P = 0.66) and 12-month (9.1% vs. 9.3%, respectively; P = 0.94) major adverse cardiac events. After adjustment, no significant differences for major adverse cardiac events were noted, but the rate of nonfatal myocardial infarction was lower in overlapping homogeneous DES group (odds ratio: 4.20, P = 0.03).
  
  
  CONCLUSIONS
  In this analysis, there were no significant differences in major adverse cardiac events between the 2 types of overlapping DES for diffuse lesions in small coronary arteries, except for higher nonfatal myocardial infarction in overlapping heterogeneous DES.
authors.affiliation: Cardiovascular Institute and Fuwai Hospital, Department of Cardiology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
authors.forename: Sheng Wen
authors.initials: SW
authors.lastname: Liu
authors.forename: Shu Bin
authors.initials: SB
authors.lastname: Qiao
authors.forename: Bo
authors.initials: B
authors.lastname: Xu
authors.forename: Feng Huan
authors.initials: FH
authors.lastname: Hu
authors.forename: Jue
authors.initials: J
authors.lastname: Chen
authors.forename: Jin Qing
authors.initials: JQ
authors.lastname: Yuan
authors.forename: Yong Jian
authors.initials: YJ
authors.lastname: Wu
authors.forename: Yue Jin
authors.initials: YJ
authors.lastname: Yang
authors.forename: Ji Lin
authors.initials: JL
authors.lastname: Chen
authors.forename: Run Lin
authors.initials: RL
authors.lastname: Gao
mesh_terms: D000328:Adult; D000368:Aged; D019917:Blood Vessel Prosthesis Implantation / Q000379:methods*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000401:mortality / Q000628:therapy*; D003331:Coronary Vessels; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000627:therapeutic use*
chemical_list: D050257:Tubulin Modulators; D017239:Paclitaxel